Cover Image
市場調查報告書

全球經皮藥物遞輸市場:策略性分析、技術、競爭企業簡介、財務評估、產品平台評估及SWOT研究

GLOBAL TRANSDERMAL DRUG DELIVERY MARKET to 2020 Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation

出版商 Kelly Scientific Publications 商品編碼 320895
出版日期 內容資訊 英文 280 Pages
訂單完成後即時交付
價格
Back to Top
全球經皮藥物遞輸市場:策略性分析、技術、競爭企業簡介、財務評估、產品平台評估及SWOT研究 GLOBAL TRANSDERMAL DRUG DELIVERY MARKET to 2020 Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation
出版日期: 2015年02月20日 內容資訊: 英文 280 Pages
簡介

本報告提供全球經皮藥物遞輸市場上市場規模、區隔、主要企業、SWOT分析、帶來影響的技術及產業、經濟環境相關整體分析,為您概述為以下內容。

第1章 摘要整理

第2章 經皮藥物遞輸

  • 簡介
  • 到現在為止的經皮藥物遞輸的發展
  • 皮膚:生物結構、生理功能
  • 經皮藥物遞輸的影響因素
  • 強化經皮藥物遞輸的策略
  • 經皮給藥及其他手法的比較
  • 經皮藥物遞輸的優點
  • 經皮給藥的缺點
  • 經皮治療的併發症

第3章 經皮藥物遞輸影響的生物動態及藥理學因素

  • 經皮藥物遞輸的影響因素
  • 經皮藥物的設計
  • 市售的經皮藥物檢驗用皮膚模式
  • 經皮藥物遞輸系統的體外檢驗

第4章 經皮藥物遞輸技術

  • 簡介
  • 小胞性經皮媒介
  • 經皮吸收貼片
  • 無貼片經皮給藥系統
  • 定量經皮系統
  • 經皮藥物遞輸用聚合物
  • 促進經皮給藥的物理手法
  • 電泳及離子導入是如何影響藥物遞輸的、其他

第5章 奈米技術如何轉換了經皮藥物遞輸

  • 概要
  • 奈米技術型的經皮藥物遞輸
  • 皮膚疾病用奈米粒子、奈米乳液
  • 奈米貼片
  • Inocyte:表皮性藥物遞輸系統、其他

第6章 經皮藥物遞輸及病情

  • 抗老化產品
  • 癌症
  • 心血管疾病
  • 慢性疲勞症候群
  • 避孕、其他

第7章 基因治療及經皮藥物遞輸

  • 概要
  • 質體DNA及電穿孔
  • 反義療法

第8章 疫苗及經皮藥物技術

  • 簡介
  • 目前技術
  • 經皮疫苗的用途

第9章 全球藥物遞輸市場

  • 概要、分析
  • 美國的藥物遞輸市場
  • 歐洲的藥物遞輸市場
  • 新興藥物遞輸市場
  • 先進藥物遞輸形勢

第10章 經皮藥物遞輸企業的商務簡介及策略性評估

  • Actavis
  • Actelion
  • GlaxoSmithKline
  • Bayer
  • Mylan Pharmaceuticals
  • Novartis
  • Upsher-Smith
  • Ascend Therapeutics
  • AMAG Pharmaceuticals (Lumara Health, KV Pharma/Ther-Rx Corp)
  • Janssen Pharmaceuticals
  • Noven Pharmaceuticals
  • ProStrakan
  • Shire
  • Hercon Pharmaceutical
  • Kremers Urban Pharmaceuticals
  • Nitto Denko
  • Teva Pharmaceutical Industries
  • Endo International
  • Teikoku USA
  • Boehringer Ingelheim
  • 3M
  • UCB
  • ParPharm

第11章 經皮藥物遞輸企業的財務分析

  • Actavis
  • Actelion
  • GlaxoSmithKline
  • Bayer
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Shire
  • Nitto Dento
  • Teva Pharmaceuticals
  • Endo International
  • Boehringer Ingelheim
  • 3M
  • UCB
  • ParPharm

第12章 目前市售經皮給藥產品

  • Actavis
  • Actelion
  • GlaxoSmithKline
  • Bayer
  • Mylan Pharmaceuticals
  • Novartis
  • Upsher-Smith
  • Ascend Therapeutics
  • AMAG Pharmaceuticals (Lumara Health)
  • Lavipharm
  • Noven Pharmaceuticals
  • ProStrakan
  • Shire
  • Hercon Pharmaceutical
  • Kremers Urban Pharmaceuticals
  • Nitto Denko
  • Teva Pharmaceutical Industries
  • Endo International
  • Teikoku USA
  • 3M
  • UCB
  • ParPharm

第13章 經皮藥物遞輸市場的詳細的SWOT分析

  • 市場促進要素
  • 經皮藥物遞輸市場抑制因素、弱點
  • 市場機會
  • 進入障礙

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 2014TDDM

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 320 tables & figures over 280 pages. This report is presented as follows:

  • By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO)
  • By Geography (Global, USA)
  • By Parent Market (Drug Delivery Systems, Advanced Drug Delivery Systems)
  • By Sub-market (Generics, Women's Health, Analgesics, Neuropathic Pain)

A wealth of financial data & business strategy information is provided including:

  • Up-to-date company financials, sales & revenue figures
  • Revenue and market forecasts
  • Business model strategies for drug delivery, pharmaceutical and biotechnology companies
  • Comprehensive account of company products, financials & portfolios

SWOT, Economic & Regulatory Environment specifics include:

  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Technologies driving the market (e.g., chemical enhancers, microneedles)
  • Top fastest growing market segments and emerging opportunities
  • Top pharmaceutical companies within the market
  • Comprehensive product portfolios, R&D activity and pipeline products
  • M&A activity and future strategies of top companies
  • High demand and unmet need enhances the market
  • Challenges of the transdermal drug delivery market

Who should read this report?

  • Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
  • Industry professionals and business strategists will discover key information to propel their policies
  • Investors will gain inside information to dominant players in the industry and future forecasts
  • Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment

C-Suite professionals, Decision Makers, Business Development professionals

This report will tell you if the companies mentioned are:

  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity

This detailed report is supported with 320 figures and tables over 280 pages and profiles the main pharmacos in the transdermal drug delivery market.

Benefits of Investing in our Cutting-Edge Reports:

  • Clients receive complementary content* with mid-level and enterprise wide licences
  • Post-sale complementary consultation with senior expert analyst is included
  • Use of tables and figures in your own reports and presentations is permitted
  • Each report provides straight-talking strategic analysis & sector intelligence
  • All reports are updated each quarter to give you the most up-to-date information

Table of Contents

1.0 Executive Summary

  • 1.1 Objectives of Report
  • 1.2 Data Sources & Methodology
  • 1.3 Key Findings & Observations
    • 1.3.1 The Global Drug Delivery Market has a Growth Rate of 5%
    • 1.3.2 The Transdermal Drug Delivery Market is Growing Vertically
    • 1.3.3 Who are the Leading Players in the Market?
    • 1.3.4 Neurodegenerative Disorders Such as Alzheimer's and Parkinson's Disease Will Propel the Future Market
    • 1.3.5 Why is the Transdermal Drug Delivery Market so Promising?
    • 1.3.6 What are the Main Drivers of the Market?
    • 1.3.7 First, Second and Third Generation Drug Delivery Systems
    • 1.3.8 The Niche Market of Commercially Available Skin Models
    • 1.3.9 Transdermal Drug Delivery Technologies are Providing the Market with Niche Spaces
    • 1.3.10 Nanotechnology is Transforming Transdermal Drug Delivery
    • 1.3.11 Can Transdermal Drug Delivery be Applied to Cancer Vaccination?
    • 1.3.12 Gene Therapy Advancement Using Transdermal Delivery

2.0 Transdermal Drug Delivery

  • 2.1 Introduction
  • 2.2 Developments of Transdermal Drug Delivery to Date
  • 2.3 The Skin - Anatomy and Physiology
    • 2.3.1 Drug Administration via the Intracellular Pathway
    • 2.3.2 Drug Administration via the Intercellular Pathway
    • 2.3.3 Fick's Law
  • 2.4 Factors that Influence Transdermal Drug Delivery
    • 2.4.1 Parameters Influencing Skin Permeability
      • 2.4.1.1 The Vehicle
      • 2.4.1.2 Drug Concentration
      • 2.4.1.3 Partition Coefficient
  • 2.5 Strategies to Enhance Transdermal Drug Delivery
    • 2.5.1 1st Generation Delivery Systems
    • 2.5.2 2nd Generation Delivery Systems
    • 2.5.3 Chemical Enhancers
    • 2.5.4 3rd Generation Delivery Systems
  • 2.6 Comparison of Transdermal Delivery with Other Methods
  • 2.7 Advantages of Transdermal Drug Delivery
    • 2.7.1 First-Pass Metabolism
  • 2.8 Disadvantages of Transdermal Delivery
  • 2.9 Complications of Transdermal Therapy
    • 2.9.1 Overdose
    • 2.9.2 Skin Sensitivity and Reactions
    • 2.9.3 MRI-Induced Skin Burns

3.0 Biomechanical and Pharmacological Elements Effecting Transdermal Drug Delivery

  • 3.1 Factors That Influence Transdermal Drug Delivery
    • 3.1.1 Rate of Permeation Across the Skin
    • 3.1.2 Skin Characteristics
    • 3.1.3 Drug Characteristics
    • 3.1.4 pH and Pharmacokinetics
  • 3.2 Transdermal Drug Design
    • 3.2.1 Factors That Affect the Absorption of the Drug
      • 3.2.1.1 Hydration and Temperature
      • 3.2.1.2 Biotransformation of the Drug in the Skin
    • 3.2.2 Selecting Drug and Vehicle
    • 3.2.3 Drug Modification
      • 3.2.3.2 Ion-Pair Formation
      • 3.2.3.3 Drug Complexation
    • 3.2.4 Thermodynamic Activity of the Drug within the Vehicle
      • 3.2.4.1 Eutectic Systems
      • 3.2.4.2 Vehicle Formulation
      • 3.2.4.3 Modification of the Stratum Corneum
  • 3.3.1 Static Franz Diffusion Cell
  • 3.4 Commercially Available Skin Models for Transdermal Drug Testing
  • 3.5 In vivo Testing of Transdermal Drug Delivery Systems
    • 3.5.1 In vivo Testing of Drug Delivery Systems
    • 3.5.2 Modelling of Transport Through the Skin

4.0 Transdermal Drug Delivery Technologies

  • 4.1 Introduction
    • 4.1.1 Local Application Formulations
    • 4.1.2 Liquid Crystals for Transdermal Drug Delivery
    • 4.1.3 Microemulsions for Transdermal Drug Delivery
    • 4.1.4 Nanoemulsions for Transdermal Drug Delivery
    • 4.1.5 Transdermal Gel Technology
    • 4.1.6 Biphasix System
    • 4.1.7 Penetration Enhancers
    • 4.1.8 Chemical Enhancers
    • 4.1.9 Nitric Oxide-Based Transdermal Drug Delivery
  • 4.2 Vesicular transdermal carriers
    • 4.2.1 Liposomes
    • 4.2.2 Transfersomes
    • 4.2.3 Ethosomes
    • 4.2.4 Elastic Vesicles
  • 4.3 Transdermal Patch
    • 4.3.1 Types of Transdermal Patch
      • 4.3.1a Single-layer Drug-in-Adhesive
      • 4.3.1b Multi-layer Drug-in-Adhesive
      • 4.3.1c Reservoir
      • 4.3.1d Matrix Patch
      • 4.3.1e Vapour Patch
    • 4.3.1 Transdermal Patches Adhesives
    • 4.3.2 New Technologies
    • 4.3.3 h-Patch™ Controlled Release Micropump System
  • 4.4 Patchless Transdermal Delivery System
  • 4.5 Metered-Dose Transdermal System
  • 4.6 Polymers for Transdermal Drug Delivery
    • 4.6.2 Film Forming Polymeric Solutions
  • 4.7 Physical Methods to Promote Transdermal Delivery
    • 4.7.1 Electrotransport
    • 4.7.2 Electroporation
      • 4.7.2.1 Drug delivery by Electroporation
      • 4.7.2.2 Electrochemotherapy
    • 4.7.3 Cryoelectrophoresis
    • 4.7.4 Iontophoresis
      • 4.7.4.1 Application of Iontophoresis for Drug Delivery
      • 4.7.4.2 Companies with Technologies for Drug Delivery by Iontophoresis
  • 4.8 How Combining Electrophoresis and Iontophoresis Impacts Drug Delivery
  • 4.9 Dermaportation
    • 4.9.1 Radiofrequency-Driven Transdermal Delivery
    • 4.9.2 Transcutaneous Drug Delivery by Electropulsation
    • 4.9.3 Skin Patch Systems and Electrostatic Force
    • 4.9.4 Heat-Aided Drug Delivery
    • 4.9.5 Ultrasound
    • 4.9.6 Magnetophoresis
  • 4.10 Use of Lasers for Transdermal Drug Delivery
    • 4.10.1 Laser-Induced Microporation
    • 4.10.2 Painless Laser Injection
    • 4.10.3 Laser-Induced Pressure Waves
      • 4.10.3.1 Transdermal Drug Delivery by Laser-Assisted Changes in Skin
  • 4.11 How Pressurized Gas is Transforming Transdermal Drug Delivery
  • 4.12 Microscission Induced by Gas
  • 4.13 Role of Microelectromechanical Systems (MEMS) in Transdermal Drug Delivery
  • 4.14 Microneedles and Dermal Microinjection
  • 4.15 Microneedle Arrays for Drug Delivery
    • 4.15.1 Microneedle Patch
    • 4.15.2 Applications of Microneedles
    • 4.15.3 AdminPatch® Microneedle Array
    • 4.15.4 Dissolving Microneedles
  • 4.16 Biodegradable Microneedles
  • 4.17 Ceramic Microneedle Arrays
  • 4.18 Dissolvable Microneedle Patches
    • 4.18.1 MicorCor
    • 4.18.2 MicroPyramid™
  • 4.19 Microstructured Transdermal Systems
  • 4.20 Microneedle Transdermal Chip
  • 4.21 Microneedle Applicator Device
  • 4.22 DebioJect ™ Microneedle Technology
  • 4.23 Silk Microneedles
  • 4.24 Tattooing
  • 4.25 ZP Patch Microprojections Technology
  • 4.26 Other Microneedle Products Currently Available
  • 4.27 Needlefree injections
  • 4.28 Glide SDI® Solid Dose Injector
  • 4.29 Jet Injection
    • 4.29.1 Why is Needle-Free so Important?
    • 4.29.2 Mini-Ject Needlefree Delivery System
    • 4.29.3 PharmaJet Stratis
    • 4.29.4 MicroJet for Painless Injections
    • 4.29.5 Nanoliter-Volume Pulsed Microjets
  • 4.30 SUMAVEL™ DosePro™ Needle-Less Injection
    • 4.31 Skin Abrasion

5.0 How Nanotechnology is Transforming Transdermal Drug Delivery

  • 5.1 Overview
  • 5.2 Nanotechnology-Based Transdermal Drug Delivery
    • 5.2.1 Nanobiotechnology for Transdermal Application
  • 5.3 Nanoparticles and Nanoemulsions for Skin Disorders
  • 5.4 Nanopatches
    • 5.4.1 Vaxxas Nanopatch Technology
    • 5.4.2 Effect of Mechanical Flexion on Penetration of Bucky Amino Acids Through the Skin
  • 5.5 Inocyte™ Epidermal Drug Delivery System
  • 5.6 Ionic Nanoparticle Technology
  • 5.7 Solid Lipid Nanoparticles (SLN) Gels
  • 5.8 siRNA- Nanoparticle Conjugates
  • 5.9 Transdermal Nanoparticle Preparations for Systemic Effect
  • 5.10 Micellar Nanoparticle Estradiol Emulsion (MNPEE)
  • 5.11 Transferosomes
  • 5.12 Nanocarriers
  • 5.13 Nanotechnology for Vaccination and Immunotherapy
  • 5.14 Safety Issues of Applications of Nanomaterial Carriers on the Skin
  • 5.15 Comparison of Current Transdermal Drug Delivery Systems

6.0 Transdermal Drug Delivery and Disease States

  • 6.1 Antiaging Products
  • 6.2 Cancer
    • 6.2.1 δ-Amino Levulinic Acid
    • 6.2.2 Breast Cancer & Afimoxifene Gel
    • 6.2.3 Cervical Cancer & Interferon α2b
    • 6.2.4 Prostate Cancer & Nitroglycerine
    • 6.2.5 Prostate Cancer & Estradiol Gel
    • 6.2.6 Prostate Cancer & Leuprolide Acetate
    • 6.2.7 Skin Cancer & Caffeine
    • 6.2.6 Cancer Vaccines
      • 6.2.6.1 Intradermal Delivery Using Adenoviral Vectors
      • 6.2.6.2 Peptide Cancer Vaccines
      • 6.2.6.3 Electroporation of Anticancer Agents
  • 6.3 Cardiovascular Disease
    • 6.3.1 Transdermal Anticoagulants
    • 6.3.2 Angina Pectoris
    • 6.3.3 Atherosclerotic Cardiovascular Disease
      • 6.3.3.1 Transdermal Oestrogen for Prevention of Atherosclerotic Cardiovascular Disease
    • 6.3.4 Congestive Heart Failure
    • 6.3.5 Hypertension
      • 6.3.5.1 Clonidine
      • 6.3.5.2 β-Blockers
      • 6.3.5.3 Calcium Channel Blockers
  • 6.4 Chronic Fatigue Syndrome
  • 6.5 Contraception
    • 6.5.1 Female Contraception
      • 6.5.1.1 Agile Therapeutics AG200-15
      • 6.5.1.2 BAY86-5016 / FC Patch Low BAY86-5016
      • 6.5.1.3 Desogestrel
      • 6.5.1.4 Ortho Evra™
    • 6.5.2 Male Contraception
      • 6.5.2.1 Transdermal Progestin Plus Testosterone
  • 6.6 Diabetes
    • 6.6.1 Insulin Drug Delivery
      • 6.6.1.1 V-Go
      • 6.6.1.2 GLP1 Agonist
  • 6.7 Men's Health
    • 6.7.1 Benign Prostatic Hypertrophy
      • 6.7.1.2 Tamsulosin Transdermal Drug Delivery System
    • 6.7.2 Erectile Dysfunction
      • 6.7.2.1 Topical and Transdermal Preparation for Erectile Dysfunction
    • 6.7.3 Hypogonadism
      • 6.7.3.1 Topical Testosterone
  • 6.8 Musculoskeletal Disease
    • 6.8.1 Osteoarthritis
    • 6.8.2 Osteoporosis
      • 6.8.2.1 Alendronate
      • 6.8.2.2 Estrogen
      • 6.8.2.3 Human Parathyroid Hormone
  • 6.9 Nausea and Vomiting
    • 6.9.1 Chemotherapy-Induced
    • 6.9.2 Motion Sickness
    • 6.9.3 Postoperative Vomiting
  • 6.10 Neurological Disease
    • 6.10.1 Alzheimer's Disease
      • 6.10.1.1 Arecoline
      • 6.10.1.2 Rivastigmine
      • 6.10.1.3 Donepezil
  • 6.11 Attention Deficit Hyperactivity Disorder
    • 6.11.1 Methylphenidate
  • 6.12 Bipolar Disorder
    • 6.12.1 Lithium
  • 6.13 Depression
    • 6.13.1 Antidepressants
    • 6.13.2 Selective Serotonin-Reuptake Inhibitors
    • 6.13.3 Fluoxetine
    • 6.13.4 Monoamine Oxidase Inhibitors
    • 6.13.5 Selegiline
    • 6.13.6 Trazodone Hydrochloride
    • 6.13.7 Venlafaxine
    • 6.13.8 Bupropion
  • 6.14 Epilepsy
  • 6.15 Migraine
    • 6.15.1 Sumatriptan
    • 6.15.2 Zolmitriptan
  • 6.16 Parkinson's Disease
    • 6.16.1 Introduction
    • 6.16.2 Dopamine Agonists
      • 6.16.2.1 Levodopa
      • 6.16.2.2 Rotigotine
    • 6.16.3 Other Agents
  • 6.17 Restless Leg Syndrome
    • 6.17.1 Rotigotine
  • 6.18 Schizophrenia
    • 6.18.1 Haloperidol
    • 6.18.2 Risperidone
    • 6.18.3 Blonanserin
  • 6.19 Tinnitus/Vertigo
    • 6.22.1 Nicotine
  • 6.20 Tourette syndrome
  • 6.21 Multiple Sclerosis
  • 6.22 Respiratory diseases
    • 6.22.1 Asthma and Chronic Obstructive Pulmonary Disease (COPD)
  • 6.23 Skin disorders
    • 6.23.1 Cutaneous Leishmaniasis
    • 6.23.2 Hair Loss
    • 6.23.3 Iontophoretic Drug Delivery for Nail Disorders
    • 6.23.4 Psoriasis
    • 6.23.4.1 Nanoemulsions for Paxitacel in Psoriasis
    • 6.23.4.2 Iontophoresis for Treatment of Psoriasis
  • 6.24 Overactive Bladder and Urinary Incontinence
    • 6.24.1 Oxybutynin
  • 6.25 Pain
    • 6.25.1 Chronic Pain
    • 6.25.2 Transdermal Local Anesthetics
    • 6.25.3 Transdermal Fentanyl for the Management of Postoperative Pain
    • 6.25.4 Fibromyalgia
    • 6.25.5 Minor Medical Procedures
    • 6.25.6 Neuralgia
    • 6.25.6.1 Lidoderm
    • 6.25.7 Nonsteroidal Anti-Inflammatory Drugs
    • 6.25.7.1 Topical NSAIDs
    • 6.25.8 Ketoprofen
    • 6.25.9 Opioids
    • 6.25.10 Cancer Pain
    • 6.25.10.1 Fentanyl
    • 6.25.10.2 Nitroglycerine
    • 6.25.10.3 Buprenorphine
  • 6.26 Smoking Cessation
    • 6.26.1 Nicotine Replacement Therapy
    • 6.26.2 Nicotine Patch in Pregnancy
  • 6.27 Viral infections
    • 6.27.1 Transdermal Nanoparticles for Immune Enhancement in HIV
  • 6.28 Women's Health
    • 6.28.1 Dysmenorrhea
    • 6.28.2 Female Infertility
    • 6.28.3 Female Sexual Arousal Disorder
    • 6.28.4 Menopause
    • 6.28.4.1 Hormone Replacement Therapy
    • 6.28.5.2 Estradiol
    • 6.28.5.3 Parathyroid Hormone for Postmenopausal Osteoporosis
    • 6.28.5.4 Testosterone and Low Libido
  • 6.29 Transdermal Nutraceuticals

7.0 Gene Therapy and Transdermal Drug Delivery

  • 7.1 Overview
  • 7.2 Plasmid DNA and Electroporation
    • 7.2.1 TriGrid™ Delivery System
    • 7.2.2 CELLECTRA®
    • 7.2.3 Magnetic Pulse Electroporation
  • 7.3 Antisense Therapy

8.0 Vaccines and Transdermal Drug Technology

  • 8.1 Introduction
    • 8.1.1 The Skin as an Immune Organ
    • 8.1.1.1 Langerhans Cells- Epidermal Antigen Presenting Cells
    • 8.1.1.2 Keratinocytes- Immune Competent Epithelial cells
    • 8.1.1.3 Dendritic Epidermal T Cells (DETC) γδ T cells -Specialised Resident Epithelial Cells
    • 8.1.1.4 Epidermotropic T lymphocytes-Circulating T Cells that home to the Epidermis
    • 8.1.1.5 Melanocytes-Epidermal Pigment Cells With Immune Properties
  • 8.2 Current Technologies
    • 8.2.1 Dissolvable Microneedle Array
    • 8.2.2 Electroporation for Administering DNA Vaccines
    • 8.2.3 Microneedles for Transdermal Vaccine Delivery
    • 8.2.4 Needle-Free Delivery of Vaccines
  • 8.3 Applications for Transdermal Vaccination
    • 8.3.1 HIV/AIDS Vaccine
    • 8.3.2 Transdermal DNA Influenza Vaccine
    • 8.3.3 Transdermal Aβ Vaccine for Alzheimer's Disease
    • 8.3.4 Transdermal Vaccine for Traveller's Diarrhoea

9.0 Global Drug Delivery Market

  • 9.1 Overview and Analysis
  • 9.2 USA Drug Delivery Market
  • 9.3 European Drug Delivery Market
  • 9.4 Emerging Drug Delivery Markets
  • 9.5 The Advanced Drug Delivery Landscape
  • 9.6 Transdermal Drug Delivery Market
  • 9.7 Smoking Cessation Drug Market
    • 9.7.1 Nicotine Replacement Therapeutics
    • 9.7.2 Non-Nicotine Containing Therapeutics
    • 9.7.3 Smoking Cessation Products in the Pipeline
  • 9.8 Neurodegenerative Disorders Such as Alzheimer's & Parkinson's disease will Propel the Future Market
  • 9.9 How Transdermal Systems Relate to the Global Pain Market
    • 9.9.1 Neuropathic Pain Market (US, UK, France, Germany, Japan, Spain and Italy) 2014-2020
    • 9.9.2 Transdermal Products Within the Neuropathic Pain Market
  • 9.10 How Transdermal Systems Relate Within the Generic Market
  • 9.11 Duragesic and Generic Fentanyl Transdermal System Competition
  • 9.12 Lidocaine Market Analysis
  • 9.13 Who are the Leading Players in the Market?
  • 9.14 What is Driving the Transdermal Drug Delivery Market?
  • 9.15 Increased Number of Geriatric and Pediatric Patients is Propelling the Market
  • 9.16 Unmet Needs Within the Transdermal Drug Delivery Market
  • 9.17 Women's Health Market

10.0 Transdermal Drug Delivery Company Business Profiles and Strategic Evaluation

  • 10.1 Actavis
  • 10.2 Actelion
  • 10.3 GlaxoSmithKline
  • 10.4 Bayer
  • 10.5 Mylan Pharmaceuticals
  • 10.6 Novartis
  • 10.7 Upsher-Smith
  • 10.8 Ascend Therapeutics
  • 10.9 AMAG Pharmaceuticals (Lumara Health, KV Pharma/Ther-Rx Corp)
  • 10.10 Janssen Pharmaceuticals
  • 10.11 Noven Pharmaceuticals
  • 10.12 ProStrakan
  • 10.13 Shire
  • 10.14 Hercon Pharmaceutical
  • 10.15 Kremers Urban Pharmaceuticals
  • 10.16 Nitto Denko
  • 10.17 Teva Pharmaceutical Industries
  • 10.18 Endo International
  • 10.19 Teikoku USA
  • 10.20 Boehringer Ingelheim
  • 10.21 3M
  • 10.22 UCB
  • 10.23 ParPharm

11.0 Transdermal Drug Delivery Company Financial Analysis

  • 11.1 Actavis
  • 11.2 Actelion
  • 11.3 GlaxoSmithKline
  • 11.3.1 ViiV Healthcare
  • 11.4 Bayer
  • 11.5 Janssen Pharmaceuticals (Johnson & Johnson)
  • 11.6 Shire
  • 11.7 Nitto Dento
  • 11.8 Teva Pharmaceuticals
  • 11.9 Endo International
  • 11.10 Boehringer Ingelheim
  • 11.11 3M
  • 11.12 UCB
  • 11.13 ParPharm

12.0 Current Transdermal Drug Delivery Products on the Market

  • 12.1 Actavis
    • 12.1.1 Androderm
    • 12.1.2 Fentanyl Transdermal System
    • 12.1.3 Lidocaine Topical Patch
    • 12.1.4 Oxytrol
  • 12.2 Actelion
    • 12.2.1 Vachlor Gel (mechlorethamine)
  • 12.3 GlaxoSmithKline
    • 12.3.1 Niquitin/Nicoderm
  • 12.4 Bayer
  • 12.5 Mylan Pharmaceuticals
    • 12.5.1 Clonidine Transdermal System
    • 12.5.2 EMSAM (Selegiline Transdermal System)
    • 12.5.3 Estradiol Transdermal System
    • 12.5.4 Fentanyl Transdermal System
    • 12.5.5 Nitroglycerin Transdermal System
    • 12.5.6 XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System)
  • 12.6 Novartis
    • 12.6.1 Exelon Patch (Rivastigmine Transdermal System)
    • 12.6.2 Duragesic - Fentanyl Patches
    • 12.6.3 Transderm Scop - Scopolamine Patches
  • 12.7 Upsher-Smith
    • 12.7.1 Vogelxo - Testosterone (1%) Gel
  • 12.8 ASCEND Therapeutics
    • 12.8.1 EstroGel®
  • 12.9 AMAG Pharmaceuticals (Lumara Health)
    • 12.9.1 Evamist®
  • 12.10.1 OrthoEvra®
    • 12.10.2 Duragesic®
  • 12.11 Lavipharm
    • 12.11.1 Fentadur
    • 12.11.2 Nicotine Transdermal Patch
    • 12.11.3 Acne Transdermal Patch
    • 12.11.4 Trinipatch
  • 12.12 Noven Pharmaceuticals
    • 12.12.1 Minivelle®
    • 12.12.2 CombiPatch®
    • 12.12.3 Daytrana®
  • 12.13 ProStraken
    • 12.13.1 Sancuso®
  • 12.14 Shire
    • 12.14.1 Daytrana® CII
  • 12.15 Hercon Pharmaceuticals
    • 12.15.1 Nitroglycerin Transdermal System
  • 12.16 Kremers Urban Pharmaceuticals
    • 12.16.1 Nitroglycerin Transdermal System
  • 12.17 Nitto Dento
    • 12.17.1 Bisono Tape
    • 12.17.2 Penles Tape
    • 12.17.3 Passport Advanced Drug Delivery System
  • 12.18 Teva Pharmaceuticals
    • 12.18.1 Zecuity
    • 12.18.2 Transdermal Fentanyl (generic)
    • 12.18.3 Tev Tropin
  • 12.19 Endo International
    • 12.19.1 Lidoderm®Patch
    • 12.19.2 Fortesa Gel
  • 12.20 Teikoku
    • 12.20.1 Lidoderm® 1
    • 12.20.2 IontoPatch®
  • 12.21 3M
    • 12.21.1 3M Fentanyl Transdermal Delivery System
    • 12.21.2 3M Rivastigmine Transdermal Delivery System
    • 12.21.3 Microneedles
  • 12.22 UCB
    • 12.22.1 Neupro®
  • 12.23 ParPharm
    • 12.23.1 Fentanyl Transdermal System

13.0 In-Depth SWOT Analysis of the Transdermal Drug Delivery Market

  • 13.1 Drivers of the Market
    • 13.1.1 Patent Expirations and Introduction of Generics
    • 13.1.2 Increased Patient Compliance Rates
    • 13.1.3 Increased Rate of Chronic Conditions and Application of Patch Technology to These Areas
    • 13.1.4 Increased Geriatric and Pediatric Drug Administration Requirements
  • 13.2 Restraints and Weaknesses of the Transdermal Drug Delivery Market
    • 13.2.1 Technical Restraints
    • 13.2.2 Drug Adverse Reactions
    • 13.2.3 Drug Failures
  • 13.3 Opportunities Within the Market Place
    • 13.3.1 High number of Pharmaco & Drug Delivery Company Collaboration
    • 13.3.2 Increasing Indications and Disease States for Transdermal Administration
    • 13.3.3 Large Opportunity for Home Health Care Market and OTC
    • 13.3.4 Targeted Drug Delivery
  • 13.4 Barriers to Market Entry
Back to Top